188 related articles for article (PubMed ID: 24572052)
21. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y
Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542
[TBL] [Abstract][Full Text] [Related]
22. Anti-Uterine Fibroid Effect of Standardized Labisia Pumila Var. Alata Extracts In Vitro and in Human Uterine Fibroid Cancer Xenograft Model.
Zakaria N; Mohd KS; Ahmed Saeed MA; Ahmed Hassan LE; Shafaei A; Al-Suede FSR; Memon AH; Ismail Z
Asian Pac J Cancer Prev; 2020 Apr; 21(4):943-951. PubMed ID: 32334454
[TBL] [Abstract][Full Text] [Related]
23. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
24. Loss of cyclin g1 expression in human uterine leiomyoma cells induces apoptosis.
Kwon SH; Park JC; Ramachandran S; Cha SD; Kwon KY; Park JK; Park JW; Bae I; Cho CH
Reprod Sci; 2008 Apr; 15(4):400-10. PubMed ID: 18497347
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
26. Liposomal 2-Methoxyestradiol Nanoparticles for Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model.
Borahay MA; Vincent KL; Motamedi M; Tekedereli I; Salama SA; Ozpolat B; Kilic GS
Reprod Sci; 2021 Jan; 28(1):271-277. PubMed ID: 32632769
[TBL] [Abstract][Full Text] [Related]
27. Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Darpolor MM; Kennealey PT; Le HC; Zakian KL; Ackerstaff E; Rizwan A; Chen JH; Sambol EB; Schwartz GK; Singer S; Koutcher JA
NMR Biomed; 2011 Nov; 24(9):1159-68. PubMed ID: 21994185
[TBL] [Abstract][Full Text] [Related]
28. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells.
Brüsselbach S; Nettelbeck DM; Sedlacek HH; Müller R
Int J Cancer; 1998 Jul; 77(1):146-52. PubMed ID: 9639406
[TBL] [Abstract][Full Text] [Related]
30. Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy.
Newcomb EW; Tamasdan C; Entzminger Y; Arena E; Schnee T; Kim M; Crisan D; Lukyanov Y; Miller DC; Zagzag D
Cell Cycle; 2004 Feb; 3(2):230-4. PubMed ID: 14712094
[TBL] [Abstract][Full Text] [Related]
31. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
Bonvini P; Zorzi E; Mussolin L; Monaco G; Pigazzi M; Basso G; Rosolen A
Haematologica; 2009 Jul; 94(7):944-55. PubMed ID: 19535344
[TBL] [Abstract][Full Text] [Related]
32. Effects of flavopiridol on critical regulation pathways of CD133high/CD44high lung cancer stem cells.
Bozok Cetintas V; Acikgoz E; Yigitturk G; Demir K; Oktem G; Tezcanli Kaymaz B; Oltulu F; Aktug H
Medicine (Baltimore); 2016 Oct; 95(43):e5150. PubMed ID: 27787370
[TBL] [Abstract][Full Text] [Related]
33. Application of metabolomics to investigate the antitumor mechanism of flavopiridol in MCF-7 breast cancer cells.
Shao X; Gao D; Wang Y; Jin F; Wu Q; Liu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():40-7. PubMed ID: 27208856
[TBL] [Abstract][Full Text] [Related]
34. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase inhibitor p27Kip1 controls growth and cell cycle progression in human uterine leiomyoma.
Ramachandran S; Kwon KY; Shin SJ; Kwon SH; Cha SD; Bae I; Cho CH
J Korean Med Sci; 2008 Aug; 23(4):667-73. PubMed ID: 18756055
[TBL] [Abstract][Full Text] [Related]
36. Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27.
Horiuchi A; Nikaido T; Ya-Li Z; Ito K; Orii A; Fujii S
Mol Hum Reprod; 1999 Feb; 5(2):139-45. PubMed ID: 10065869
[TBL] [Abstract][Full Text] [Related]
37. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity.
Newcomb EW
Anticancer Drugs; 2004 Jun; 15(5):411-9. PubMed ID: 15166614
[TBL] [Abstract][Full Text] [Related]
38. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Tsurumaru M
Dis Esophagus; 2004; 17(4):338-44. PubMed ID: 15569374
[TBL] [Abstract][Full Text] [Related]
39. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
